Nigeria’s RxAll to get $150,000 as it joins 11 global startups for Norway’s Katapault Accelerator
RxAll will receive up to $150,000 in additional funding and access to a network of global investors and corporate partners to catalyze the company’s development.
Nigeria’s Big Data and Artificial Intelligence start up for drug authentication, RxAll will be getting $150,000 after been selected to join 11 global impact startups for Norway’s Katapault Accelerator.
The start known for using spectrometry in drug authentication, is among the 12 startups selected from 1,500 applicants for the second cohort of the Katapault Accelerator in Oslo, Norway.
Known for its technology that involves the unique use of AI and deep learning algorithms to identify drug counterfeits and provide real time information to pharmaceutical companies, RxAll was selected for its exponential technology and potential to address global-scale problems with operations in Nigeria, Kenya and Singapore.
The Katapault Accelerator will provide an intensive program to leverage impact for RxAll which is building a digital platform that enables pharmacies buy directly from pharmaceutical manufacturers.
The Katapault Accelerator programme is a three-month programme that brings together impact-focused technology startups from around the world.
This year’s founders and their companies represent Africa, Asia, Europe, and North America.
At the end of the programme, each participating founder will have refined his or her vision, strategy, impact orientation, growth marketing plan, and business model.
“We are excited by the opportunity to receive additional funding and technical support from the world’s foremost impact accelerator as we expand access to safe medicines across Africa and South-East Asia,” says Adebayo Alonge, Co-Founder and CEO of RxAll.
Through the Katapault Accelerator, RxAll will have access to 120+ international mentors, and hands on support from the Katapult Accelerator team.
As part of the programme, RxAll will receive up to $150,000 in additional funding and access to a network of global investors and corporate partners to catalyze the company’s development.
RxAll has received grants and technical support from the Nigerian government, the Nigerian Federal Ministry of Health, InnovateHealthYale & the Yale Entrepreneurial Institute.
JOIN OUR PULSE COMMUNITY!
Eyewitness? Submit your stories now via social or: